About Roche
Founded in 1896, headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics.
Roche is the world’s largest biotech company with truly differentiated medicines in oncology, immunology, infectious disseases, neuroscience and cardio-metabolism.
Roche is also the world leader in in-vitro diagnostics, tissue-based
cancer diagnostics and a pioneer in diabetes management. Roche’s
personalised healthcare strategy aims at providing medicines and
diagnostic tools that enable tangible improvements in the health,
quality of life and survival of patients.
In 2012, Roche had over 82,000 employees worldwide and invested
around 8.5 billion Swiss francs in R&D. The Group posted sales of
45.5.billion Swiss francs.
The Roche innovation network
Genentech
Genentech, United States, is a wholly owned member of the Roche
Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.
For more information: www.roche.com.
Roche Group’s capabilities are augmented by technology
collaborations and a constellation of worldwide alliances to help
develop individual products and entire product portfolios.
Roche
South San Francisco, CA
Chugai
Basel, Switzerland
Penzberg, Germany
Madison, WI
Indianapolis, IN
Branford, MA
Pleasanton, CA
Mannheim, Penzberg,
Germany
Shanghai, China
Rotkreuz,
Switzerland
Ventana
Tucson, AZ
Roche has one of the strongest drug development pipelines in the
industry with over 30 phase III projects and multiple projects currently
in registration. The pipeline overall comprises over 70 new molecular
entities and over 20 additional indications for existing products. Half of
the projects in late-stage development utilise a companion diagnostic
test and thus could help advance personalised healthcare.
Tokyo, Japan
Roche Pharma,
including Genentech
Roche
Diagnostics
Majority
shareholdings
Roche is recognised as a leader in Corporate Governance and Sustainability. Roche is listed on the FTSE4 Good Indices and is the 2012 Super Sector leader for
healthcare in the Dow Jones Sustainability Indices (DJSI). Roche participates in various humanitarian and educational projects.
Pharmaceuticals Division
The Roche Group’s Pharmaceuticals division is made up of Roche Pharmaceuticals represented in over 150 countries, Genentech (the Group’s U.S. pharmaceuticals
business) and a majority shareholding of Chugai in Japan. Seven of Roche’s 10 top-selling medicines are manufactured using biotechnology, and biopharmaceuticals
account for more than 70% of pharmaceutical sales.
Global sales of top 10 medicines in 2012
MabThera/Rituxan 1,2
Herceptin 1
Avastin 1
Pegasys 3
Xeloda 1
Lucentis 4
Tarceva 1
CellCept 2
Actemra/RoActemra 2
Xolair 2
CHF billion
6.7
5.9
5.8
1.6
1.5
1.5
1.3
0.9
0.8
0.7
Sales by region 2012
Sales by therapeutic area 2012
United States 39% (+7%)
Western Europe 22% (-2%)
Japan 12% (+2%)
CEMAI5 9% (+8%)
Latin America 7% (+11%)
Asia-Pacific 8% (+15%)
Other 3% (+9%)
Roche Group’s Pharmaceuticals
division focuses on five main
therapeutic areas:
Oncology 61% (+9%)
Infectious diseases2 9% (+14%)
Immunology 9% (+5%)
CardioMetabolism 8% (-14%)
Neuroscience 2% (+1%)
Other 11% (+1%)
Diagnostics Division
Roche’s Diagnostics division is the world leader in in-vitro diagnostics;
products used to test blood and other body fluids and tissue samples to
obtain information for the diagnosis, treatment and monitoring of diseases. Its
product portfolio ranges from blood glucose meters for people with diabetes
and point-of-care testing devices for use in doctors’ offices, to high-throughput
analysers for hospitals and commercial diagnostic laboratories. The division
also supplies state of the art instruments and reagents for life science research.
Italics = growth rates as measured at constant exchange rates
1 Oncology
2 Immunology
3 Virology
Sales by region 2012
Sales by business area 2012
Roche’s Diagnostics division
consists of five business areas:
Europe, Middle East & Africa
(EMEA) 46% (-1%)
North America 26% (+3%)
Asia-Pacific 14% (+15%)
Latin America 8% (+15%)
Japan 6% (+7%)
Professional Diagnostics 51% (+8%)
Diabetes Care 25% (-4%)
Molecular Diagnostics 11% (+4%)
Applied Science 7% (-3%)
Tissue Diagnostics 6% (+12%)
4 Other
5 CEMAI - Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent
Key Financials
Contact Information
As reported in Swiss Francs (CHF)
Sales
2012
35.2
2011
10.3
32.8
2010
42.5
9.7
37.1
0
Core operating profit
45.5
47.5
10.4
25
50
17.2
2012
15.1
2011
16.6
2010
0
Operating free cash flow
10
20
15.3
2012
2011
13.7
2010
14.1
12
13
14
15
CHF billion
16
17
Per security data as reported in
Swiss Francs (CHF)
Core earnings per share (EPS)
13.62
2012
2011
12.30
2010
12.78
0.00
10.00
5.00
15.00
Dividend per share
7.351
2012
2011
6.80
2010
6.60
0.00
8.00
4.00
CHF
Pharmaceuticals
Diagnostics
1 Subject to approval at Annual General Meeting on 5 March 2013
Additional Information
This factsheet for investors contains certain forward-looking statements. These
forward-looking statements may be identified by words suchas ‘believes’, ‘expects’,
‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar
expressions or by discussion of, among other things, strategy, goals, plans or
intentions. Various factors may cause actual results to differ materially in the future
from those reflected in forward-looking statements contained in this Annual Report,
among others: (1) pricing and product initiatives of competitors; (2) legislative
and regulatory developments and economic conditions; (3) delay or inability in
obtaining regulatory approvals or bringing products to market; (4) fluctuations in
currency exchange rates and general financial market conditions; (5) uncertainties
in the discovery, development or marketing of new products or new uses of existing
products, including without limitation negative results of clinical trials or research
projects, unexpected side effects of pipeline or marketed products; (6) increased
government pricing pressures; (7) interruptions in production; (8) loss of or inability
to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss
of key executives or other employees; and (11) adverse publicity and news coverage.
The statement regarding earnings per share growth is not a profit forecast and
should not be interpreted to mean that Roche’s earnings or earnings per share for
this year or any subsequent period will necessarily match or exceed the historical
published earnings or earnings per share of Roche.
Please see www.roche.com or other Roche Group websites for full information on
products mentioned. All trademarks mentioned enjoy legal protection.
Copyright © 17 January 2013 by Roche Investor Relations North America,
South San Francisco.
F. Hoffmann-La Roche Ltd
Investor Relations
CH-4070 Basel
Switzerland
Main Switchboard: +41 61 688 1111
IR requests ONLY: +41 61 688 8880
Fax: +41 61 691 0014
investor.relations@roche.com
www.roche.com/investors
Dr. Karl Mahler
+41 (0) 61 687 8503
karl.mahler@roche.com
Dr. Nina Mojas
+41 (0)61 687 1300
nina.mojas@roche.com
Dr. Sabine Borngraeber
+41 (0)61 688 8027
sabine.borngraeber@roche.com
Elhan Webb, CFA
+41 (0)61 688 9630
elhan.webb@roche.com
Dr. Luís Correia
+41 (0)61 687 5284
luis.correia@roche.com
Tamer Farhan
+41 (0)61 688 2552
tamer. farhan@roche.com
Roche Holdings, Inc.
Genentech, Inc.
Investor Relations North America
1 DNA Way
South San Francisco CA 94080
USA
Main Number: +1 650 225 1000
Fax: +1 650 225 8326
Thomas Kudsk Larsen
+1 650 467 2016
larsen.thomas@gene.com
Nina Goworek
+1 650 467 8737
goworek.nina@gene.com
Stacy Galvin
+1 650 225 4150
galvin.stacy@gene.com
Dr. Ekaterine Kortkhonjia
+1 650 467 5873
kortkhonjia.ekaterine@gene.com